SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Female hand holds notebook with brain on yellow background
Funding
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s Program
Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy to the market.
November 20, 2025
 · 
1 min read
 · 
Tristan Manalac
Bayer office in Basel, Switzerland
Lung cancer
Bayer Wins Lung Cancer Accelerated Approval for Kinase Inhibitor
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 blocker for non-small cell lung cancer.
November 20, 2025
 · 
1 min read
 · 
Tristan Manalac
Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.
Approvals
FDA Hands Regeneron Two Eylea HD Nods in One Day
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.
November 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: Job Openings Will Likely Drop as 2025 Winds Down But Could Rise in 2026
Biopharma professionals will probably find decreasing employment opportunities this month and next even as layoffs continue, based on BioSpace data. However, hundreds of open roles are expected this year in Massachusetts, and a job market turnaround could start late next year.
November 20, 2025
 · 
4 min read
 · 
Angela Gabriel
Successful career takeoff. Profitable investment, business concept. Art collage.
Obesity
Lilly’s Weight Loss Trio Could Top $100B in Revenue Thanks to Oral Option
If Eli Lilly’s obesity pill orforglipron is approved and priced around $200 per month, analysts at Truist predict patients will flock to it.
November 19, 2025
 · 
1 min read
 · 
Annalee Armstrong
China, vector 3d flag on blue background with hud interfaces
Insights
CRO Boom in APAC Region, With China at the Forefront
The CRO market in the APAC region is thriving, particularly in China, due to intense clinical trial and innovation development, with Western investors and pharma leaning in.
November 19, 2025
 · 
5 min read
 · 
Jennifer Smith-Parker
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
FDA
Makary Eyes ‘America-First’ User Fee Structure as Renewal Negotiations Approach
A spokesperson for the FDA said the agency is “considering a wide range of options to support American innovation.”
November 19, 2025
 · 
2 min read
 · 
Tristan Manalac
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to go with its original suitor.
November 19, 2025
 · 
3 min read
 · 
Tristan Manalac
Podcast
Billions More in M&A, Another Bidding War and More FDA Drama
Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high between FDA Commissioner Marty Makary and Health Secretary RFK Jr.
November 19, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS